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Background: Symptoms of anxiety are present not only in panic disorder or other anxiety
disorders, but are highly prevalent in the general population. Despite increasing biological
research on anxiety disorders, there is little research on understanding subclinical or
sub-threshold symptoms relating to anxiety in non-clinical community samples, which
could give clues to factors relating to resilience or compensatory changes.
Aims: This study focused on brain structural correlates of subclinical
anxiety/agoraphobia symptoms from a multi-center imaging study.
Methods: We obtained high-resolution structural T1 MRI scans of 409 healthy young
participants and used the CAT12 toolbox for voxel-based morphometry (VBM) analysis.
Subjects provided self-ratings of anxiety using the SCL-90-R, from which we used the
phobia subscale, covering anxiety symptoms related to those of panic and agoraphobia
spectrum.
Results: We found significant (p < 0.05, FDR-corrected) correlations (mostly positive)
of cortical volume with symptom severity, including the right lingual gyrus and calcarine
sulcus, as well as left calcarine sulcus, superior, middle, and inferior temporal gyri.
Uncorrected exploratory analysis also revealed positive correlations with GMV in
orbitofrontal cortex, precuneus, and insula.
Conclusions: Our findings show brain structural associations of subclinical symptoms
of anxiety, which overlap with those seen in panic disorder or agoraphobia. This is
consistent with a dimensional model of anxiety, which is reflected not only functionally
but also on the structural level.
Keywords: anxiety disorders, imaging, neuroanatomy, phobias, healthy subjects, voxel-based morphometry
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INTRODUCTION
Modern psychiatry has experienced a paradigm shift from
categorical classifications of mental illness to dimensional
approaches, taking into account the clinical and neurobiological
continuum of psychopathological symptoms. This approach is
highly relevant for neurobiological research (1–4) as well as
diagnosing and treating mental illness (5). Yet, there is little
biological research to understand the full spectrum, including
its subclinical or subthreshold part, where symptoms might
be prevalent but not reaching the threshold to manifest
disorders. This includes a spectrum covering minor symptoms,
which might transiently present in clinically healthy subjects,
or “subthreshold” symptom combinations accompanied by
some clinical burden, but not reaching the threshold of a
DSM/ICD-defined clinical phenotype.While there is no generally
accepted distinction between “subclinical” and “subthreshold”
symptoms, some recent studies have referred to “subthreshold”
psychopathologies as those which (although not meeting clinical
criteria) are closer to clinical states and potentially predictive
of subsequent transition to clinical psychopathologies [for
example: (6–9)]. For the purpose of the present study, we
shall refer to subclinical symptoms as those not meting clinical
thresholds, without necessarily exceeding levels seen in the
general population, and without explicitly assuming a link to
imminent clinical stages of disorders.
Considering models of risk and resilience, the neurobiological
underpinnings of these changes might lead to a better
understanding of compensatory changes, which lead to
subclinical (as opposed to clinical) phenotypes. So far, however,
few studies have explicitly addressed the problem of neural
correlates of subclinical symptoms.
Anxiety and phobic symptoms are not only among the
most prevalent symptoms in various psychopathologies, but
anxiety disorders constitute a considerable proportion of mental
disorders (10). Common anxiety disorders are panic disorder
and agoraphobia, with typical sudden attacks of anxiety, and
anxiety about being in places or situations from which escape
might be difficult or embarrassing or in which help might not
be available in case that escape is needed, respectively (American
Psychiatric Association, Diagnostic and Statistical Manual of
Mental Disorders, 5th ed., 2013). The 12-month prevalence
of panic disorder is 1.8% in the adult, Caucasian population
aged 18–65 and around 1.3% suffer from agoraphobia (11). Not
only are these the most common and often comorbid anxiety
disorders in patients (12). Single panic attacks or mild symptoms
of agoraphobia also occur in non-clinical populations or during
stressful life-events, such as during complicated grief reactions
(13). Epidemiologic follow-up studies have shown that there
might also be a prodrome to the development of severe anxiety
disorders (next to depression or substance abuse), characterized
by panic attacks or mild agoraphobic symptoms (14–17).
Among the most common anxiety disorders associated with
phobic symptoms are panic disorders and agoraphobia. Several
recent neuroimaging studies in patients with these disorders
have shown brain structural alterations, such as increase of
gray matter volume (GMV) in left insula, superior temporal
gyrus, midbrain and pons, as well as GMV decrease in right
anterior cingulate cortex (ACC) in patients with panic disorder
(18). Patients with comorbid agoraphobia also exhibit bilaterally
decreased amygdala and left parahippocampal volume (19). A
meta-analysis covering social and generalized anxiety disorders
reported GMV reductions in right anterior cingulate and
precentral as well as left inferior frontal and middle temporal
gyri in patients. Some of these findings overlap with results from
functional neuroimaging studies revealing hyperactivation of
the ventral striatum and insula when anticipating agoraphobia-
specific situations in agoraphobic patients (20) or viewing visual
cues related to anxiety (21). However, other studies have also
identified functional changes in fusiform, lingual, and calcarine
cortices in panic disorder with agoraphobia (22). While there
is considerable heterogeneity across different disorders, a recent
meta-analysis of structural imaging across anxiety disorders (23)
has suggested that ACC and inferior frontal GMV reductions
are prevalent and might constitute a point of neurobiological
overlap. These findings also overlap with more general studies of
human fear and anxiety, which have pointed out the relevance of
the amygdala and ACC (24, 25).
Overall, this data is based on comparison of clinical
populations with healthy controls, and thus little is known about
subclinical anxiety symptoms (e.g., agoraphobic). Yet, for all we
know, many healthy controls (lacking a concurrent psychiatric
diagnosis) might experience symptoms of anxiety due to stressful
life events or even as a prodrome to later agoraphobia. It is
therefore unclear, which of the above findings relate to those
representing a putative neurobiological continuum reflecting
different degrees of anxiety, and which might relate to the
expression of a defined clinical disease phenotype.
We assembled a large cohort of participants (recruited from
the general population) for voxel-based morphometry (VBM)
analysis of subclinical agoraphobic symptoms, hypothesizing
alterations of GMV in the limbic system (e.g., amygdala), ACC
to be correlated with symptoms. We performed a whole-brain
analysis in order to also identify effects in areas not reported in
classical case-control studies of anxiety disorders. This analysis
builds on a previous study of ours (26), in which we used VBM
in a sample of 177 non-clinical (psychiatrically healthy) subjects,
correlating variation in gray matter with subclinical depression
(general), anxiety, and somatisation subscales. Analyzing a larger
multi-center cohort, our present study focuses on the “phobic”
anxiety subscale of the SCL90R, which reflects subclinical
symptoms close to the agoraphobia spectrum.
METHODS
Participants
We included 409 healthy young adults consisting of three sub-
samples. The participants were recruited as healthy controls
for ongoing case-control studies in Jena, Germany, and
Verona/Milano, Italy. The Jena sample of 318 subjects was
divided in two sub-samples for methodological reasons, resulting
in a Jena-1 sample of 177 persons and the Jena-2 sample with
141 persons scanned later on the scanner following an extensive
hardware and software upgrade, which led us to treat these
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two subject groups as separate samples. The Jena-1 sample has
previously been used for analyses of sub-clinical depressive and
anxiety symptoms, although not for the scale used in this present
study (26). The Verona-Milano sample consisted of 91 persons.
The 318 participants recruited in Jena gave written informed
consent to a study protocol approved by the local Ethics
Committee of Jena University Medical School, while the
91 participants recruited in Verona-Milano provided written
informed consent to a study protocol approved by the Ethics
Committee of the Azienda Ospedaliera Universitaria of Verona.
Inclusion criteria were ability to provide written informed
consent and an age of 18 or above. Exclusion criteria were:
current or previous psychiatric disorders (axis I), central nervous
neurological disorders, traumatic brain injury with loss of
consciousness, learning disability, or contraindication for MRI
scans. As our study design was based on a dimensional model,
we did not define symptom level thresholds, other than manifest
clinical psychiatric conditions.
None of the participants had a present or history of DSM-
IV axis I disorders, as determined by careful screening via
phone (Jena samples) resp. by a modified interview derived from
the SCID-IV non-patient version (SCID-NP) (Verona-Milano
sample). They also had no history of major neurological and
unmedicated internal medical conditions, as well as psychiatric
history in first-degree relatives.
To exclude major cognitive impairment (IQ < 80), IQ was
estimated using the MWT-B, a German language inventory
similar to the NART (27) in the two Jena samples. All Verona-
Milano participants met this criterion, but IQ was estimated
using the Italian version of the Wechsler Adult Intelligence
Scale—Revised (28, 29).
To assess subclinical occurrence of (agora)phobic symptoms,
subjects completed SCL-90-R at the time of study. The SCL-
90-R is a well established self-rating instrument to assess a
broad range of psychopathological symptoms (30), and is one
of the most widely used symptom questionnaire with over 1,000
published studies in many clinical and non-clinical samples (31).
It consists of 90 items covering multiple domains of well-being
and psychopathology, each to be rated on a 0–4 Likert-type scale,
which can then be analyzed syndrome-wise with nine different
scales. From these, we selected the “phobia” scale (scale 7), which
consists of 7 items, mainly covering agoraphobic symptoms
with emphasis on situations with low availability of help, and
avoidance behavior. Dividing the cumulating value of the scale by
the number of items we calculated the scale value (mean value),
resulting in a range from 0 to 4. An overview of demographic
and psychometric data is given in Table 1. In our pooled sample
the mean scale value was 0.077, the data did not follow a normal
distribution (Kolmogorov-Smirnov-Test with p < 0.05).
Magnetic Resonance Imaging (MRI)
Subjects for the Jena-1 sample underwent high–resolution T1-
weighted MRI on a 3 Tesla Siemens Tim Trio scanner (Siemens,
Erlangen, Germany) using a standard quadrature head coil and
an axial 3-dimensional magnetization prepared rapid gradient
echo (MP-RAGE) sequence (TR 2,300ms, TE 3.03ms, α 9◦, 192
TABLE 1 | Demographic and psychometric data on the three sub-samples.
Jena-1 Jena-2 Verona-Milano
(n = 177) (n = 141) (n = 91)
Mean age (SD) 29.8 (±8.93) 32.12 (±14.27) 29.13 (±7.7)
Age_range 20–60 19–73 18–62
Gender 83 f, 94m 87 f, 54m 55 f, 36 m
Mean IQ (SD) 106.23 (±11.5) 115.87 (±14.81) 122.39 (±8.49)
Mean SCL-90_phob
scale value (SD)
0.09 (±0.19) 0.09 (±0.24) 0.05 (±0.09)
SCL-90_phob_range 0–1.14 0–2 0–0.43
Overview of age, gender, IQ and SCL90-R aggression subscale values given as mean and
standard deviation (SD). f, female, m, male.
contiguous sagittal slices, FoV 256mm, voxel resolution 1× 1×
1mm; acquisition time 5:21min).
Participants of the Jena-2 sample were scanned on a Siemens
Prisma fit system (Siemens, Erlangen, Germany), which was
based on the above Siemens Tim Trio scanner, after undergoing a
significant upgrade (both hardware and software). The structural
scan was acquired with an MP-RAGE sequence with similar
parameters (TR 2,300ms, TE 2.07ms, α 9◦, 192 contiguous
sagittal slices, FoV 256mm, voxel resolution 1 × 1 × 1mm;
acquisition time 5:21min) as part of a 25min imaging session.
The Verona-Milano sample MRI scans were acquired with
a 3T Magnetom Allegra Syngo MR 2004A (Siemens, Erlangen,
Germany) also using a standard head coil for radio frequency
transmission and reception of the MRI signal. An MP-RAGE
sequence was acquired (TR 2,060ms, TE 3.93ms, α 15◦, 160
contiguous sagittal slices, FoV 256mm, voxel resolution 1 × 1
× 1 mm, acquisition time 7:32min). The scan was part of a MRI
protocol of about 50min total duration.
All scans were checked to exclude imaging artifacts.
Voxel-Based Morphometry
For VBM, we used the CAT 12 toolbox (Computational
Anatomy Toolbox 12) of the Structural Brain Mapping group,
Jena University Hospital, Jena, Germany (C. Gaser), which
is implemented in SPM12 (Statistical Parametric Mapping,
Institute of Neurology, London, UK). All T1-weighted images
were corrected for bias—field inhomogeneities, then segmented
into gray matter (GM), white matter (WM), and cerebrospinal
fluid (CSF) (32) and spatially normalized using the DARTEL
algorithm (33). The segmentation process was further extended
by accounting for partial volume effects (34), applying adaptive
maximum a posteriori estimations (35). After pre-processing
and in addition to visual checks for artifacts all scans passed an
automated quality check protocol. Scans were smoothed with a
Gaussian kernel of 8mm (FWHM). For exclusion of artifacts on
the gray/white matter border (i.e., incorrect voxel classification),
we applied an absolute gray matter threshold of 0.1.
Statistics
For statistical comparison, we applied the general linear model
(GLM) approach implemented in SPM12. For every analysis, we
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used scanner as a factor in order to eliminate the confounding
effects of the three different scanner (setups) used.We performed
one GLM correlating SCL-90-R phobia subscale values with
GMV. For VBM- analysis we included total intracranial volume
(TIV) as a nuisance variable in order to remove the related
variance and applied correction for multiple comparisons
at a threshold of p < 0.05, FDR-corrected. We performed
whole-brain analyses investigating both positive and negative
correlation between scale value and GMV.
In addition to this main analysis we performed an exploratory
analysis (also for future hypothesis-generation purposes) at an
uncorrected p < 0.001 threshold.
RESULTS
Cortical volume showed multiple (positive) correlations with the
SCL-90-R phobia subscale in several clusters (p < 0.05, FDR-
corrected), in particular right lingual gyrus and calcarine sulcus,
as well as left calcarine sulcus, superior, middle and inferior
temporal gyri.
Our exploratory analysis at p < 0.001 (uncorrected) revealed
positive correlations of GMV in addition to the above clusters
in left precentral and post-central gyri and precuneus as well as
right orbitofrontal cortex (OFC), insula, precuneus, and posterior
cingulate gyrus. An overview of both results is given in Table 2
and presented in Figure 1.
There were no negative correlations of gray matter with the
SCL90R phobia subscale (neither at p < 0.05 FDR-corrected, nor
p < 0.001 uncorr. levels).
While in our sample SCL-90-R phobic anxiety subscale was
not significantly correlated with either age (p= 0.44, r =−0.038,
two-tailed Pearson correlation) or gender (p= 0.638, r=−0.023,
two-tailed Pearson correlation), we additionally reanalysed the
data with those variables as nuisance variables. Overall, this
confirmed our previous analysis with significant (p < 0.05, FDR-
corrected) findings, in particular right lingual gyrus and calcarine
sulcus, as well as left calcarine sulcus, superior, middle, and
inferior temporal gyri.
DISCUSSION
In this study, we demonstrate a brain-wide pattern of GMV
associations with minor/subclinical agoraphobic symptoms
in non-clinical, psychiatrically healthy subjects. Overall, our
findings are consistent with a putative neurobiological spectrum
of anxiety, which manifests as an incremental effect of an
anxiety dimension on brain structure. However, our study
also shows some positive correlations with symptoms, thus
suggesting that an overly simplified model of linear effects
between phenotypes and their neural correlates is not likely to
explain the complex relationship between phenotypes and brain
structural variation.While there are only very few studies relating
anxiety symptoms to brain morphology, we shall discuss our
findings in comparison to case-control studies of agoraphobia
and panic disorder.
A study focussing on trait anxiety (as determined by the T-
AI measuring anxiety related trait personality) in 382 university
students found a negative correlation with GMV in the right
middle occipital gyrus (36). The authors argued that conscious-
level visual processing might be impaired in persons with higher
trait anxiety, but the lack a functional anatomical model as
well as effects in the functional MRI part of the same study
in this area limit further interpretation of those findings. In a
study on social anxiety in 130 healthy adults social distress was
correlated with the cortical volume of the right OFC and left
amygdala, while social avoidance was correlated with the cortical
volume of the right dorsolateral prefrontal cortex (DLPFC) (37).
Also, a study in n = 320 adults showed positive associations of
separation anxiety scores with increased amygdala GMV (38).
In our own previous work, a VBM study of the Jena-1 sample
(177 healthy subjects) using the general anxiety scale of the SCL-
90-R, which reflects more general symptoms rather than those
reflected in the phobia scale, we previously showed positive GMV
correlations with subclinical symptoms of general anxiety in
middle temporal gyrus, Rolandic operculum, middle cingulate
gyrus, and precuneus bilaterally (26). Hence, the findings diverge
in particular for the occipital cortical findings, which were only
present in the current multi-center study of the agoraphobic
anxiety scale.
Although there seems to be some overlap of findings in these
studies of healthy subjects, the comparison suffers from the
considerable heterogeneity of tools used to measure duration
and quality of anxiety symptoms. To our knowledge, there is
currently no other study on brain structural correlates of mild
agoraphobic symptoms in healthy participants.
Nonetheless, alterations in insula, cingulate, and temporal
cortices and OFC have robustly been shown in previous case-
control studies of generalized anxiety disorder, specific phobia,
social anxiety disorder, panic disorders, and agoraphobia (18, 20,
23). In the panic disorder/agoraphobia spectrum, several studies
appear to converge on effects in the amygdala, ACC, insula, and
lateral prefrontal cortex, but also for occipital brain areas. This
indicates a partial overlap with our findings (although not for
key regions like the ACC), and thus supports the notion of a
biological continuum at least in some brain areas.
GMV reduction in the amygdala of patients with panic
disorder was found in early studies (39–41), although not all
studies (42), but it is unclear whether this is also present in
agoraphobia (18). GMV alterations in insula and ACC were
repeatedly replicated in patients with panic disorders, hinting
at participation of these areas in the evaluation of (negative)
emotional meaning of potentially distressing cognitive and
interoceptive sensory information. It was also hypothesized that
altered brain stem structures could mediate panic attacks (40).
Temporal volume reductions in patients with panic disorder
occurred mainly in right inferior and left superior temporal
gyri. The same study also reported GMV reductions in right
inferior and left superior frontal gyri, right precuneus and
bilateral putamen (43). Also, decreased GMV was found in left
medial OFC in patients with panic disorder and agoraphobia,
but not without agoraphobia, suggesting the area especially
involved in phobic avoidance of certain situations (44). Another
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TABLE 2 | Overview of significant clusters of positive correlations of GMV with SCL-90-R phobia subscale values.
Anatomical region Co-ordinates of peak voxel k p (peak-level) T
Main, FDR-corrected analysis
Right lingual gyrus and bilateral calcarine sulcus 10; −87; −8 308 0.017 5.12
Left superior and middle temporal gyrus −45; −22; 0 14 0.024 4.45
Right calcarine sulcus 15; −102; 0 30 0.036 4.19
Inferior and middle temporal gyrus −56; −8; −28 22 0.037 4.16
Exploratory, uncorrected analysis (exp.voxels/cluster, k = 101.83)
Right lingual gyrus, bilateral calcarine 10; −87; −8 1,190 0.0001 5.12
sulcus, right cuneus, and cerebellum (BA6) 15; −102; 0 4.19
Left superior and middle temporal gyri −45; −22; 0 119 0.0001 4.45
Left middle and inferior temporal gyri −56; −8; −28 434 0.0001 4.16
−48; −14; −27 3.87
Left precentral and post-central gyri −33; −27; 45 101 0.0001 4.01
Right OFC and insula 42; 33; −6 258 0.0001 3.92
Left lingual gyrus and calcarine sulcus −9; −82; −6 124 0.0001 3.87
Bilateral precuneus 6; −62; 33 134 0.0001 3.82
Left lingual gyrus and calcarine sulcus −4; −75; 8 203 0.0001 3.8
−6; −68;4 3.45
K, cluster size (voxel).
FIGURE 1 | Positive correlations of GMV with SCL-90-R phobia subscale value in 409 healthy controls VBM-results are presented as maximum intensity projections
(gray color indicates areas of significant positive correlations) and slice overlays on a gray matter average image of the whole sample yellow color indicates areas of
significant positive correlation. We performed (A) brain-wide analysis with p < 0.05, FDR-corrected and (B) an exploratory brain-wide analysis with p < 0.001,
uncorrected.
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study implicates a neurodevelopmental background for volume
reduction of the posterior region of the OFC in patients with
panic disorder, since the area receivesmultisensory input (45, 46).
A particularly noteworthy result of our study is the effect of
phobic anxiety in posterior, mostly occipital, cortices, which in
fact survived correction for multiple comparisons. Lingual cortex
changes (reduction in patients compared to controls) was found
in one previous study, which included panic disorder patients
with co-morbid depression, so specificity of findings remains
unclear (47). Functional MRI reports detected lowered activation
in fusiform and inferior occipital gyri, the calcarine sulcus,
cerebellum, and cuneus, as well as higher activity in precuneus
in patients with panic disorder and agoraphobia compared with
healthy controls, when confronted with emotionally neutral
pictures of faces and places. The authors suggest higher anxiety-
related arousal in those patients (22). A recent functional
MRI study has, however, also suggested that some of these
effects are seen across multiple anxiety disorders, hence again
questioning specificity (21). Other functional changes of in
panic disorder include metabolic changes studied with MR
spectroscopy. Patients with panic disorder exhibit a 22%
reduction in total occipital cortex GABA concentration (GABA
plus homocarnosine) (48). Interestingly, occipital regions of
visual processing appeared to be enlarged in patients with social
anxiety disorder, and have been linked to abnormal emotional
information processing (49), although this finding has not been
replicated in a more recent study (50). While a recent meta-
analysis of anxiety and mood disorders has associated aberrant
activations in occipital cortices with emotional experiences
(51), it appears that our understanding of these changes is
still very incomplete and necessitates further study and model
development.
Heterogeneity in our samples might be related to liability for
agoraphobia as well as resilience toward the full expression of
a clinical phenotype. Subjects with particular brain structural
features (e.g., in the insula and other regions) might be
particularly prone not only to subthreshold symptoms, but might
have a higher incidence of clinical anxiety disorders. However, it
remains unclear how this might interact with protective factors,
which themselves might be associated with regional gray matter
enlargement and thus prevent the gray matter reduction seen
in clinically manifest disorders. Since we did not have follow-
up data to study subjects who later might have developed
agoraphobia or another anxiety disorder, our analysis remains
cross-sectional.
We conclude that even temporary agoraphobic symptoms,
which might be related to stressful life episodes, have an
impact on cortical volume of healthy people in part similar
to patients. Additional areas like primary visual cortex also
correspond with functional and metabolic findings in patients
in some anxiety disorders, suggesting these areas importance
for early pathogenesis. Investigating a homogeneous sample
of healthy young adults possibly enables detection of areas
otherwise statistically not significant when comparing patients
to controls without diagnosis but an uncharted amount of
mild agoraphobic symptoms. Interestingly, many correlations in
our study were positive, echoing recent findings in subclinical
symptoms, while in clinically manifest disorders, categorical
effects mostly show volume reductions in patients. This might
be explained by different factors. We propose that the association
between symptoms and regional graymatter, when studied across
the full spectrum (from minor sub-clinical to increased sub-
clinical, to sub-threshold clinical, and finally manifest clinical
expressions of the phenotype) might be non-linear. For example,
if the association was best represented by an “inverted U
shape” curve, one would reasonably expect positive (linear)
correlation when restricting the analysis to the lower end (non-
clinical) spectrum, while correlations in the higher end of the
spectrum (i.e., clinically manifest disorder) would show negative
correlations, i.e., gray matter loss with increasing severity of
symptoms. However, our results might also be related to
uncontrolled confounders sharing variance with the SCL90R
score.
The brain structural variations identified here might not
only relate to liability for agoraphobia; indeed, they might
also relate to compensatory changes on a structural level,
which ultimately result in a non-clinical phenotype. Studies
of subclinical symptoms are, however, still scarce and often
limited to small samples. Yet, they hold a potential to better
understand the interactions of liability or risk vs. resilience,
and the neural sequelae of this dynamic process, which
might result in the expression of a disease phenotype vs.
temporal expression of subclinical symptoms. Given the recent
importance placed in identification of biotypes of anxiety
disorders (52), our findings argue for also considering the full
spectrum of psychopathology and a spectrum approach, which
takes into account both categorical as well as dimensional
expressions of symptoms in patients as well as the general
population.
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